uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain Nasdaq:QURE

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain Nasdaq:QURE

News Highlights

LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (News) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that three manuscripts on preclinical data from its gene therapy candidate AMT-130 in Huntington’s disease have been accepted for publication, in the journals Science Translational Medicine, Brain Science, and Brain Communications. The publications show the safety and efficacy of AMT-130 in the deep brain structures of a large animal model and outline a promising novel efficacy biomarker for AMT-130.

“Taken together, these publications demonstrate widespread biodistribution and strong, durable efficiency of AMT-130 in disease-relevant regions in a large brain,” stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. “The data provide further support for the potential therapeutic value of AMT-130, and we remain enthusiastic about our Phase I/II clinical trial of AMT-130 in patients with Huntington’s disease.”

Widespread and Sustained Target Engagement in Huntington Disease Minipigs

The paper published this week in Science Translational Medicine examines the translatability and long-term durability of AMT-130 in transgenic Huntington’s disease minipigs, which were used to assess the biodistribution and target engagement in a larger brain. The minipig model is the largest diseased animal model available, generally weighing up to 300 pounds.  

AMT-130 was administered by MRI-guided convention-enhanced delivery (CED) at a single dose, bilaterally in the caudate and putamen. Vector DNA distribution and transgene expression in minipig brains demonstrated extensive brain coverage comparable at the interim sacrifice timepoints of 6- and 12-months post administration, leading to significant lowering of mutant huntingtin (mHTT) protein in the brain.

At 12 months, the most pronounced mHTT protein lowering was observed in the putamen (85%), caudate (80%) and amygdala (78%), followed by thalamus (56%) and cerebral cortex (44%).

The publication, “Widespread and Sustained Target Engagement in Huntington Disease Minipigs upon Intrastriatal MicroRNA-based Gene Therapy,” is available online in the journal Science Translational Medicine (DOI: 10.1126/scitranslmed.abb8920).

Well-tolerated in non-human primates and rats

In addition, a GLP toxicity study of AMT-130 in non-human primates and rats was published in January 2021 in the journal Brain Science. The study demonstrated an excellent safety profile and biodistribution after MRI-guided CED of AMT-130 in the treated animals. One-time bilateral administration in the caudate and putamen resulted in widespread vector DNA and miHTT transgene distribution in the brain, particularly in areas associated with HD pathology. Intrastriatal administration of AAV5-miHTT was well tolerated, with no clinically relevant changes in either species.

The publication, “Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology,” is available online in the journal Brain Science (DOI: 10.3390/brainsci11020129).

Monitoring Durability of MicroRNA-based Therapies

A third manuscript was published last week in the journal Brain Communications, examining the potential use of measuring therapeutic HTT microRNA (miHTT) in extracellular vesicles in CSF as sources to monitor the expression and durability of gene therapies in the brain. After AAV treatment in non-human primates, the secretion of mature engineered microRNA molecules was confirmed, with extracellular microRNA levels correlating with viral dose and cellular microRNA expression in neurons. In investigating the detection of engineered microRNAs over time in the CSF of non-human primates after a single intrastriatal injection of AAV5-miHTT, quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion.

The results confirm the long-term expression (up to two years) of AAV5-delivered microRNAs in non-human primates and provide further support for the potential use of extracellular vesicle-associated microRNAs as novel biomarkers in ongoing clinical trials of gene therapies for neurodegenerative diseases, including AMT-130.

The publication, “Secreted therapeutics: Monitoring durability of microRNA-based gene therapies in the central nervous system,” is available online in the journal Brain Communications (DOI: 10.1093/braincomms/fcab054).

About AMT-130

AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that lowers Huntingtin protein in Huntington’s disease patients. AMT-130 is uniQure’s first clinical program incorporating its proprietary miQURE™ platform. miQURE is designed to degrade disease-causing genes without off-target toxicity and induce silencing of the entire target organ through secondary exosome-mediated delivery.

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to whether we will advance our Phase I/II gene therapy clinical trial of AMT-130 in Huntington’s disease. uniQure’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the ongoing COVID-19 pandemic on our Company and the wider economy and health care system, our Commercialization and License Agreement with CSL Behring, the regulatory approval of that transaction, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading “Risk Factors” in uniQure’s periodic securities filings, including its Annual Report on Form 10-K filed March 1, 2021. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

  • Check the latest Health news updates and information.
  • Please share this news uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain Nasdaq:QURE with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Strive presents the first application focused on cryptography and digital piggy bank

Strive presents the first application focused on cryptography and digital piggy bank

‘Penny the Pig’ piggybanks are priced at $149 USD (£106.87 GBP) each and can be pre-ordered from the Strive website.  “Without a doubt, the crypto market is ...
LSO investigating theft of catalytic converter in welding companies

LSO investigating theft of catalytic converter in welding companies

Source www.1011now.com If you know anything about this case, call LSO investigators at (402) 441-6500. Deputies said employees believe the theft could have ...
That Ghosts ‘n Goblins Resurrection Game Is Coming to PS4 – Push Square

That Ghosts ‘n Goblins Resurrection Game Is Coming to PS4 – Push Square

When Ghosts ‘n Goblins Resurrection hit Nintendo’s hybrid system back in February, our chums over at Nintendo Life seemed to enjoy the masochistic ...
Apple vendor Quanta says there is no business impact from the ransomware attack

Apple vendor Quanta says there is no business impact from the ransomware attack

Source www.reuters.com Our Standards: The Thomson Reuters Trust Principles. Quanta said it was working with law enforcement and data protection authorities ...
Activision Could Face a Trademark Suit by 2021 Strategy Game Dev

Activision Could Face a Trademark Suit by 2021 Strategy Game Dev

Charges were filed in the District Court for the Central District of California on April 8 as what the company alleges is a response to Ficker’s threat of ...
Venmo launches buying and selling cryptography

Venmo launches buying and selling cryptography

– Now you can use your Venmo app to buy, sell, and hold Bitcoin and other cryptocurrencies. PayPal launched the service Tuesday on its popular digital money ...
Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021 Nasdaq:PCRX

Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021 Nasdaq:PCRX

News Highlights PARSIPPANY, N.J., April 21, 2021 (News) — Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter ...
HIMSS offers recommendations on the role of digital health in vaccine distribution

HIMSS offers recommendations on the role of digital health in vaccine distribution

Capitalise on health information and technology and data systems to support robust, globally coordinated, comprehensive COVID-19 vaccination plans. Exercise ...
Mayor expanding San Diego’s free internet program with more locations

Mayor expanding San Diego’s free internet program with more locations

The $500,000 program aims to establish free wireless internet at more than 300 new locations and provide city libraries 900 new mobile hotspots and hundreds ...
Branch-of-one workforce with integrated access, security and network package targeted by VMware

Branch-of-one workforce with integrated access, security and network package targeted by VMware

VMware Anywhere Workspace brings together the company’s core enterprise software products, including its Workspace ONE unified endpoint management offering, ...
Show next
Compsmag - Latest News from tech, business and health
Logo